Pages that link to "Q42925485"

The following pages link to Vascular endothelial growth factor: much more than an angiogenesis factor (Q42925485):

Displaying 29 items.

• Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism (Q24303934) (← links)
• Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer (Q26748924) (← links)
• Distinct Functions of Neutrophil in Cancer and Its Regulation (Q26773228) (← links)
• Keratinocytic vascular endothelial growth factor as a novel biomarker for pathological skin condition (Q26822766) (← links)
• Biosensors in clinical practice: focus on oncohematology (Q27027114) (← links)
• miR-21 improves the neurological outcome after traumatic brain injury in rats (Q30596128) (← links)
• VEGF targets the tumour cell (Q33573324) (← links)
• Vascular endothelial growth factor-A is associated with chronic mountain sickness in the Andean population. (Q33820044) (← links)
• Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary tale (Q34261539) (← links)
• Evidence underlying the clinical management of diabetic macular oedema. (Q34889065) (← links)
• Macrophage-Derived Tumor Necrosis Factor-α Is an Early Component of the Molecular Cascade Leading to Angiogenesis in Response to Aortic Injury (Q35041234) (← links)
• Progression of choroidal metastasis of ovarian serous cystoadenocarcinoma after intravitreal bevacizumab treatment (Q36928730) (← links)
• Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward? (Q37094060) (← links)
• Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). (Q37329315) (← links)
• VEGF and podocytes in diabetic nephropathy (Q38041671) (← links)
• Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth (Q39413595) (← links)
• VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug (Q41186469) (← links)
• Clinicopathological investigation of vascular endothelial growth factor and von Hippel-Lindau gene-related protein expression in immunohistochemically negative pituitary adenoma--possible involvement in tumor aggressiveness (Q44312255) (← links)
• High-altitude adaptation in humans: from genomics to integrative physiology (Q46659572) (← links)
• Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed? (Q47136084) (← links)
• Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy. (Q48050678) (← links)
• Hypoxia paradoxically inhibits the angiogenic response of isolated vessel explants while inducing overexpression of vascular endothelial growth factor (Q51557632) (← links)
• Surface plasmon resonance biosensor for the detection of VEGFR-1--a protein marker of myelodysplastic syndromes. (Q54558737) (← links)
• Epigallocatechin gallate & curcumin prevent transforming growth factor beta 1-induced epithelial to mesenchymal transition in ARPE-19 cells. (Q54955039) (← links)
• VEGF genetic polymorphisms may contribute to the risk of diabetic nephropathy in patients with diabetes mellitus: a meta-analysis (Q59100561) (← links)
• Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates (Q62566471) (← links)
• Inhibition of vascular endothelial growth factor in young adult mice causes low bone blood flow and bone strength with no effect on bone mass in trabecular regions (Q64285306) (← links)
• Pretruncal Subarachnoid Hemorrhage and High Cerebral Blood Flow Velocities With Bevacizumab Therapy (Q85074438) (← links)
• VEGF expands erythropoiesis via hypoxia-independent induction of erythropoietin in noncanonical perivascular stromal cells (Q90462781) (← links)